| 1 |
2023 |
Antibacterial Mechanism of 2R,3R-Dihydromyricetin Against Staphylococcus aureus: Deciphering Inhibitory Effect on Biofilm and Virulence Based on Transcriptomic and Proteomic Analyses. |
DMY |
| 2 |
2022 |
Bioassay-guided isolation and characterization of lead antimicrobial compounds from Acacia hydaspica plant extract. |
Atl, CG, FnBP, MG |
| 3 |
2022 |
Fibrin(ogen) engagement of S. aureus promotes the host antimicrobial response and suppression of microbe dissemination following peritoneal infection. |
--- |
| 4 |
2022 |
Molecular Detection of Clumping factor A gene and Antibiotic Susceptibility Evaluation of Staphylococcus Aureus Isolated from Urinary Tract Infections. |
S. aureus |
| 5 |
2022 |
Protein-conjugated microbubbles for the selective targeting of S. aureus biofilms. |
MBs, S. aureus |
| 6 |
2021 |
Adaptation of Staphylococcus aureus to the Human Skin Environment Identified Using an ex vivo Tissue Model. |
fnbA, SigB, WTA |
| 7 |
2021 |
Influence of Nisin-Biogel at Subinhibitory Concentrations on Virulence Expression in Staphylococcus aureus Isolates from Diabetic Foot Infections. |
agrI, AMP, Atl, coa, DFIs, icaA, icaD, MIC, SpA |
| 8 |
2021 |
PIA and rSesC Mixture Arisen Antibodies Could Inhibit the Biofilm-Formation in Staphylococcus aureus. |
BAIs, FTIR, PIA |
| 9 |
2020 |
Evaluation of the Efficacy of a Cholera-Toxin-Based Staphylococcus aureus Vaccine against Bovine Intramammary Challenge. |
IFN-gamma, IgG, IsdA, S. aureus, SCC |
| 10 |
2019 |
Liposomal and CpG-ODN formulation elicits strong humoral immune responses to recombinant Staphylococcus aureus antigens in heifer calves. |
CpG ODN, FnBPA, Lip |
| 11 |
2019 |
Mechanostability of the Fibrinogen Bridge between Staphylococcal Surface Protein ClfA and Endothelial Cell Integrin alphaVbeta3. |
Fg |
| 12 |
2018 |
Assessment of the Dual Role of Clumping Factor A in S. Aureus Adhesion to Endothelium in Absence and Presence of Plasma. |
ECs, Fg, FN, FnBPA, vWbp, vWF |
| 13 |
2018 |
Immunogenicity of a Staphylococcus aureus-cholera toxin A2/B vaccine for bovine mastitis. |
IsdA |
| 14 |
2018 |
Marginal role of von Willebrand factor-binding protein and coagulase in the initiation of endocarditis in rats with catheter-induced aortic vegetations. |
Coa, IE, vWbp |
| 15 |
2018 |
Staphylococcus aureus clumping factor A is a force-sensitive molecular switch that activates bacterial adhesion. |
Fg |
| 16 |
2017 |
Adaptive Upregulation of Clumping Factor A (ClfA) by Staphylococcus aureus in the Obese, Type 2 Diabetic Host Mediates Increased Virulence. |
PAI-1, T2D |
| 17 |
2017 |
Clumping factor A of Staphylococcus aureus interacts with AnnexinA2 on mammary epithelial cells. |
--- |
| 18 |
2017 |
Clumping factor A, von Willebrand factor-binding protein and von Willebrand factor anchor Staphylococcus aureus to the vessel wall. |
S. aureus, SrtA, vWbp, vWF |
| 19 |
2017 |
Mouse model of hematogenous implant-related Staphylococcus aureus biofilm infection reveals therapeutic targets. |
AT |
| 20 |
2017 |
Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach. |
BiSAbs, mAb, mAbs, MRSA |
| 21 |
2017 |
The Staphylococcus aureus Cell Wall-Anchored Protein Clumping Factor A Is an Important T Cell Antigen. |
--- |
| 22 |
2016 |
Contribution of Staphylococcus aureus Coagulases and Clumping Factor A to Abscess Formation in a Rabbit Model of Skin and Soft Tissue Infection. |
coa, vWbp |
| 23 |
2016 |
Inhibition of major integrin alphaV beta3 reduces Staphylococcus aureus attachment to sheared human endothelial cells. |
EC, S. aureus |
| 24 |
2016 |
Preclinical Efficacy of Clumping Factor A in Prevention of Staphylococcus aureus Infection. |
--- |
| 25 |
2016 |
Protective efficacy of the chimeric Staphylococcus aureus vaccine candidate IC in sepsis and pneumonia models. |
IC, IsdB, OPA |
| 26 |
2016 |
Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study. |
CP5 and CP8 |
| 27 |
2016 |
Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial. |
cLIA, FBI, ICS, OPA, S. aureus |
| 28 |
2016 |
Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection. |
--- |
| 29 |
2016 |
Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcusaureus Disease. |
AT, mAb, OPK |
| 30 |
2015 |
A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. |
CP5 and CP8, CRM197 |
| 31 |
2015 |
Construction of scFv that bind both fibronectin-binding protein A and clumping factor A of Stapylococcus aureus. |
BM, FnBPA, VH, VL |
| 32 |
2015 |
Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection. |
FBI |
| 33 |
2015 |
Evaluation of approaches to monitor Staphylococcus aureus virulence factor expression during human disease. |
MntC, qRT-PCR, SA4Ag |
| 34 |
2015 |
In silico analysis for identifying potential vaccine candidates against Staphylococcus aureus. |
--- |
| 35 |
2015 |
New potential role of serum apolipoprotein E mediated by its binding to clumping factor A during Staphylococcus aureus invasive infections to humans. |
APOE |
| 36 |
2015 |
Protection of mice against Staphylococcus aureus infection by a recombinant protein ClfA-IsdB-Hlg as a vaccine candidate. |
IsdB |
| 37 |
2015 |
Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial. |
AEs, AT, GMCs, pIMDs, SAEs, TT |
| 38 |
2015 |
Vaccination against Staphylococcus aureus experimental endocarditis using recombinant Lactococcus lactis expressing ClfA or FnbpA. |
FnBPA, IE |
| 39 |
2014 |
A short sequence within subdomain N1 of region A of the Staphylococcus aureus MSCRAMM clumping factor A is required for export and surface display. |
MSCRAMM |
| 40 |
2013 |
Immunogenicity analysis of Staphylococcus aureus clumping factor A genetic variants. |
--- |
| 41 |
2013 |
Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins. |
GlcNAc, SDR |
| 42 |
2013 |
Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis. |
CPS, dHla |
| 43 |
2013 |
Two Dimensional Structural Analysis and Expression of a New Staphylococcus aureus Adhesin Based Fusion Protein. |
FnBPA, HGF, VRSA |
| 44 |
2012 |
A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. |
Fg |
| 45 |
2012 |
Protective immunization against Staphylococcus aureus infection in a novel experimental wound model in mice. |
Eap, Efb, FnBP |
| 46 |
2012 |
Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A. |
dPNAG |
| 47 |
2011 |
Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity. |
--- |
| 48 |
2011 |
Evaluation of a novel chimeric B cell epitope-based vaccine against mastitis induced by either Streptococcus agalactiae or Staphylococcus aureus in mice. |
IgG, rSip-ClfA, Sip |
| 49 |
2011 |
Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. |
Coa, vWbp |
| 50 |
2010 |
Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. |
--- |
| 51 |
2010 |
Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A. |
IL-17A |
| 52 |
2009 |
c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection. |
i.v, IgG1, MRSA, mSEC, s.c |
| 53 |
2009 |
Differential binding of biofilm-derived and suspension-grown Staphylococcus aureus to immobilized platelets in shear flow. |
--- |
| 54 |
2009 |
Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. |
S. aureus |
| 55 |
2009 |
Regional profiling for determination of genotype diversity of mastitis-specific Staphylococcus aureus lineage in Canada by use of clumping factor A, pulsed-field gel electrophoresis, and spa typing. |
PFGE |
| 56 |
2009 |
Relationship between virulence factor genes in bovine Staphylococcus aureus subclinical mastitis isolates and binding to anti-adhesin antibodies. |
Efb, FnBPA |
| 57 |
2009 |
[Immunogenicity of Staphylococcus aureus recombinant clumping factor A]. |
S. aureus |
| 58 |
2008 |
A new feasible method for fibrinogen purification based on the affinity of Staphylococcus aureus clumping factor A to fibrinogen. |
GST |
| 59 |
2008 |
A structural model of the Staphylococcus aureus ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics. |
Fg, IIb |
| 60 |
2008 |
Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. |
CP, SCVs |
| 61 |
2008 |
Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for Staphylococcus aureus virulence. |
--- |
| 62 |
2008 |
Genotypic screening of atypical Staphylococcus aureus strains isolated from clinical samples for presence of selected adhesin genes. |
bbp, cna, fnbA, fnbB |
| 63 |
2008 |
Repeat-based subtyping and grouping of Staphylococcus aureus from human infections and bovine mastitis using the R-domain of the clumping factor A gene. |
--- |
| 64 |
2008 |
Signal peptides direct surface proteins to two distinct envelope locations of Staphylococcus aureus. |
FnBPB, SasA |
| 65 |
2008 |
Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b. |
rClfA |
| 66 |
2008 |
Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. |
FnBPA |
| 67 |
2007 |
A segment of Staphylococcus aureus clumping factor A with fibrinogen-binding activity (ClfA221-550) inhibits platelet-plug formation in mice. |
--- |
| 68 |
2007 |
Bacterial c-di-GMP is an immunostimulatory molecule. |
DCs |
| 69 |
2007 |
Both complement- and fibrinogen-dependent mechanisms contribute to platelet aggregation mediated by Staphylococcus aureus clumping factor B. |
--- |
| 70 |
2007 |
Capsular polysaccharide masks clumping factor A-mediated adherence of Staphylococcus aureus to fibrinogen and platelets. |
CP |
| 71 |
2007 |
Fibrinogen and elastin bind to the same region within the A domain of fibronectin binding protein A, an MSCRAMM of Staphylococcus aureus. |
MSCRAMM |
| 72 |
2007 |
Fibronectin-binding proteins and clumping factor A in Staphylococcus aureus experimental endocarditis: FnBPA is sufficient to activate human endothelial cells. |
ECs, FnBPA, IE |
| 73 |
2007 |
In vivo sortase A and clumping factor A mRNA expression during Staphylococcus aureus infection. |
GyrB, SrtA |
| 74 |
2007 |
Molecular basis for Staphylococcus aureus-mediated platelet aggregate formation under arterial shear in vitro. |
FnBPA, IE |
| 75 |
2006 |
Clumping factor A of Staphylococcus aureus inhibits phagocytosis by human polymorphonuclear leucocytes. |
--- |
| 76 |
2006 |
DNA immunization of dairy cows with the clumping factor A of Staphylococcus aureus. |
IRES |
| 77 |
2005 |
ClfA(221-550), a fibrinogen-binding segment of Staphylococcus aureus clumping factor A, disrupts fibrinogen function. |
--- |
| 78 |
2005 |
Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis. |
FnBPA |
| 79 |
2005 |
Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants. |
IVIG, PKs, SdrG |
| 80 |
2004 |
A fibrinogen-binding protein of Staphylococcus lugdunensis. |
--- |
| 81 |
2004 |
Characterization of the fibrinogen-binding surface protein Fbl of Staphylococcus lugdunensis. |
--- |
| 82 |
2004 |
Clumping factor A-mediated virulence during Staphylococcus aureus infection is retained despite fibrinogen depletion. |
--- |
| 83 |
2004 |
Expression of staphylococcal clumping factor A impedes macrophage phagocytosis. |
--- |
| 84 |
2004 |
Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows. |
FnBP, IRES, pCI-bGM-CSF |
| 85 |
2003 |
Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. |
IE, MRSA |
| 86 |
2003 |
Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. |
mAb |
| 87 |
2002 |
DNA immunization against the clumping factor A (ClfA) of Staphylococcus aureus. |
--- |
| 88 |
2002 |
Staphylococcus and biofilms. |
Aap, Bap, dltA, IS, PIA |
| 89 |
2001 |
Clumping factor A mediates binding of Staphylococcus aureus to human platelets. |
--- |
| 90 |
2001 |
Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. |
--- |
| 91 |
2001 |
Reassessing the role of Staphylococcus aureus clumping factor and fibronectin-binding protein by expression in Lactococcus lactis. |
fnbA |
| 92 |
2001 |
Study of Staphylococcus aureus pathogenic genes by transfer and expression in the less virulent organism Streptococcus gordonii. |
--- |
| 93 |
2000 |
Expression of Staphylococcus aureus clumping factor A in Lactococcus lactis subsp. cremoris using a new shuttle vector. |
--- |
| 94 |
2000 |
Heterologously expressed Staphylococcus aureus fibronectin-binding proteins are sufficient for invasion of host cells. |
FnBPs |
| 95 |
2000 |
Identification of residues in the Staphylococcus aureus fibrinogen-binding MSCRAMM clumping factor A (ClfA) that are important for ligand binding. |
Fg |
| 96 |
1998 |
The fibrinogen-binding MSCRAMM (clumping factor) of Staphylococcus aureus has a Ca2+-dependent inhibitory site. |
--- |
| 97 |
1997 |
Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. |
--- |
A Search Service for Abbreviation / Long Form
